Table 1.
The clinicopathological features of patients
| Clinicopathological features | Patients (n = 400) |
|---|---|
| Male, n (%) | 338 (84.5) |
| Age, mean ± SD, years | 54 (47–64) |
| Cirrhosis, n (%) | |
| Hepatitis B | 328 (82.0) |
| Non-alcoholic steatohepatitis | 21 (5.3) |
| Hepatitis C | 2 (0.5) |
| Alcohol-related liver disease | 46 (11.5) |
| Other | 3 (0.8) |
| AFP, ng/mL | 18.5 (4.3–438.2) |
| CEA, ng/mL | 2.3 (1.6–3.8) |
| CA125, ng/mL | 10.0 (7.8–14.8) |
| Alanine aminotransferase, U/L | 25.0 (17.0–37.8) |
| Aspartate aminotransferase, U/L | 27.0 (20.2–36.0) |
| Total bilirubin, μmol/L | 12.1 (8.8–15.4) |
| Pathology, n (%) | Lesions (n = 432) |
| HCC | 368 (85.2) |
| G1 | 159 (39.8) |
| G2 | 64 (16.0) |
| G3 | 145 (36.3) |
| Intrahepatic cholangiocarcinoma | 22 (5.1) |
| Combined hepatocellular-cholangiocarcinoma | 4 (0.9) |
| Epithelioid hemangioendothelioma | 1 (0.3) |
| Leiomyosarcoma | 1 (0.3) |
| Carcinosarcoma | 2 (0.5) |
| Adenocarcinoma | 1 (0.3) |
| Metastases | 2 (0.5) |
| Hemangioma | 11 (2.5) |
| Focal nodular hyperplasia | 16 (3.7) |
| Angiomyolipoma | 1 (0.3) |
| Hepatocellular adenoma | 1 (0.3) |
| Regenerative nodules or dysplastic nodules | 2 (0.5) |
AFP alphafetoprotein, CEA carcinoembryonic antigen, CA125 carbohydrate antigen125